NK cells for high-risk blood cancers before transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–74 with good overall health status, OR age 75+ with excellent health and no major frailty
- Specific HLA blood type (C1/C1 or C2/C2) — determined by a blood test
- Adequate liver, kidney, lung, and heart function
- Off steroids and immunosuppressive medications for at least 28 days before treatment
- At least 2 weeks since last chemotherapy (timing varies by drug type)
- No active infections, no heart attack in the past 6 months, and ability to use contraception for 4 months after infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Hear when a new Relapsed Adult AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.